Compare Lennar Corporation (LEN) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Medtronic PLC — how do they compare? Lennar Corporation trades at $76.69 (market cap $18.44B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 6.1× Lennar Corporation's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Medtronic PLC for 63 Days on average.
| LEN | MDT | |
|---|---|---|
Market Cap | $18.44B | $112.24B |
Volume | 6,012,214 | 105,663,236 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $105.35 |
52-Week Low | $74.44 | $73.75 |
Typical Hold Time | 67 Days | 63 Days |
Enterprise Value | $22.86B | $131.58B |
Dividend Yield | 2.58% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $77.6, up 1.93% on the day, but remains in a bearish technical trend with recent earnings misses and declining profitability. The stock is trading below its book value with a P/B of 0.86, indicating potential undervaluation, while Berkshire Hathaway's increasing stake to 11.2% provides notable institutional support. Revenue and net income have softened in 2025, with margins under pressure amid a challenging housing market.
The outlook is mixed: strong institutional backing and attractive valuation metrics suggest long-term opportunity, but near-term headwinds from rising mortgage rates, earnings volatility, and bearish technical signals pose risks. Analyst consensus is divided, with a $77.38 price target slightly below the current price, reflecting cautious optimism amid sector uncertainty.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 49-year dividend growth streak. The stock shows bearish technical signals but maintains solid profitability with 13.93% net margins and positive cash flow trends. Recent regulatory approvals for medical devices and raised guidance signal operational momentum despite mixed technical indicators.
Outlook remains positive with analyst consensus at $97.80 (11% upside) and no sell ratings, though technical weakness and increasing debt-to-asset ratios pose near-term risks. The 3.2% dividend yield provides income support while revenue growth acceleration to $37.5B projected for 2026 offers growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
